Loading...
600521 logo

Zhejiang Huahai Pharmaceutical Co., Ltd.SHSE:600521 Stock Report

Market Cap CN¥24.4b
Share Price
CN¥16.40
CN¥17.87
8.2% undervalued intrinsic discount
1Y5.0%
7D-4.0%
Portfolio Value
View

Zhejiang Huahai Pharmaceutical Co., Ltd.

SHSE:600521 Stock Report

Market Cap: CN¥24.4b

Zhejiang Huahai Pharmaceutical (600521) Stock Overview

Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. More details

600521 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends3/6

600521 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Zhejiang Huahai Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zhejiang Huahai Pharmaceutical
Historical stock prices
Current Share PriceCN¥16.40
52 Week HighCN¥27.97
52 Week LowCN¥14.37
Beta0.18
1 Month Change-2.84%
3 Month Change4.39%
1 Year Change4.99%
3 Year Change-13.46%
5 Year Change-18.12%
Change since IPO598.53%

Recent News & Updates

Recent updates

Analysis Article Feb 20

Cautious Investors Not Rewarding Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Performance Completely

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 37x, you may consider...
Analysis Article Jan 27

Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Somewhat Strained Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Oct 22

Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Zhejiang Huahai Pharmaceutical Co., Ltd.'s ( SHSE:600521 ) price-to-earnings (or "P/E") ratio of 27.5x might make it...
Analysis Article Sep 25

Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Jun 20

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Key Insights The projected fair value for Zhejiang Huahai Pharmaceutical is CN¥32.64 based on 2 Stage Free Cash Flow to...
Analysis Article May 28

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article May 06

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Zhejiang Huahai Pharmaceutical Co., Ltd.'s ( SHSE:600521 ) recent soft profit numbers didn't appear to worry...
Analysis Article Mar 22

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider...

Shareholder Returns

600521CN PharmaceuticalsCN Market
7D-4.0%-4.6%-1.1%
1Y5.0%-1.2%34.0%

Return vs Industry: 600521 exceeded the CN Pharmaceuticals industry which returned 0.5% over the past year.

Return vs Market: 600521 underperformed the CN Market which returned 33.8% over the past year.

Price Volatility

Is 600521's price volatile compared to industry and market?
600521 volatility
600521 Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement6.4%
10% most volatile stocks in CN Market10.0%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 600521 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 600521's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19899,065Bao Hua Chenwww.huahaipharm.com

Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals.

Zhejiang Huahai Pharmaceutical Co., Ltd. Fundamentals Summary

How do Zhejiang Huahai Pharmaceutical's earnings and revenue compare to its market cap?
600521 fundamental statistics
Market capCN¥24.44b
Earnings (TTM)CN¥373.17m
Revenue (TTM)CN¥8.55b
65.5x
P/E Ratio
2.9x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600521 income statement (TTM)
RevenueCN¥8.55b
Cost of RevenueCN¥3.58b
Gross ProfitCN¥4.98b
Other ExpensesCN¥4.60b
EarningsCN¥373.17m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.25
Gross Margin58.20%
Net Profit Margin4.36%
Debt/Equity Ratio87.7%

How did 600521 perform over the long term?

See historical performance and comparison

Dividends

1.5%
Current Dividend Yield
78%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 05:03
End of Day Share Price 2026/05/19 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Huahai Pharmaceutical Co., Ltd. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wanhua WuChina International Capital Corporation Limited
Andy LiuChina Stock Investment Research Co. Ltd. (GZ500..com)
Jie YaoCitic Securities Co., Ltd.